CA2718943A1 - Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists - Google Patents

Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists Download PDF

Info

Publication number
CA2718943A1
CA2718943A1 CA2718943A CA2718943A CA2718943A1 CA 2718943 A1 CA2718943 A1 CA 2718943A1 CA 2718943 A CA2718943 A CA 2718943A CA 2718943 A CA2718943 A CA 2718943A CA 2718943 A1 CA2718943 A1 CA 2718943A1
Authority
CA
Canada
Prior art keywords
opioid
antagonist
prodrug
opioid agonist
abuse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2718943A
Other languages
English (en)
French (fr)
Inventor
Audra Lynn Stinchcomb
Stan Lee Banks
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zynerba Pharmaceuticals Inc
Original Assignee
Alltranz Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alltranz Inc filed Critical Alltranz Inc
Publication of CA2718943A1 publication Critical patent/CA2718943A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2718943A 2008-03-26 2009-03-26 Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists Abandoned CA2718943A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3976308P 2008-03-26 2008-03-26
US61/039,763 2008-03-26
PCT/US2009/038439 WO2009120889A2 (en) 2008-03-26 2009-03-26 Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists

Publications (1)

Publication Number Publication Date
CA2718943A1 true CA2718943A1 (en) 2009-10-01

Family

ID=40809924

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2718943A Abandoned CA2718943A1 (en) 2008-03-26 2009-03-26 Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists

Country Status (6)

Country Link
US (1) US20090246265A1 (enExample)
EP (1) EP2254561A2 (enExample)
JP (1) JP2011515495A (enExample)
CA (1) CA2718943A1 (enExample)
MX (1) MX2010010512A (enExample)
WO (1) WO2009120889A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4458376A4 (en) * 2022-01-30 2025-05-07 Zhejiang University PH-REACTIVE ANALGESIC FOR TARGETING DAMAGED DORSAL ROOT GANGLION SEGMENT AND USE THEREOF

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
CA2687979C (en) 2007-05-25 2017-07-04 Tolmar Therapeutics, Inc. Sustained delivery formulations of risperidone compounds
KR101660996B1 (ko) * 2008-09-16 2016-09-28 넥타르 테라퓨틱스 남용에 대한 낮은 잠재성을 갖는 페길화 오피오이드
US8386274B1 (en) 2008-09-17 2013-02-26 Mckesson Financial Holdings Limited Systems and methods for a prescription safety network utilizing eligibility verification transactions
ES2592277T3 (es) * 2010-04-02 2016-11-29 Buzzz Pharmaceuticals Limited Formulaciones transdérmicas disuasorias del abuso de agonistas y agonistas-antagonistas opiáceos
US8392219B1 (en) 2010-05-10 2013-03-05 Mckesson Financial Holdings Limited Systems and methods for streamlined patient enrollment for one or more healthcare programs
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
GB2481619B (en) * 2010-06-30 2012-06-20 Londonpharma Ltd Formulations and delivery devices for the sublingual administration of opioids
US20120225112A1 (en) * 2011-03-03 2012-09-06 Mark Stephen Saia Method and Apparatus for Alcohol Administration
US9566341B1 (en) 2011-04-27 2017-02-14 University Of Kentucky Research Foundation Compounds including Cox inhibitor moiety and enhanced delivery of active drugs using same
US20130017259A1 (en) 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
US9283175B2 (en) 2011-07-28 2016-03-15 Ian S. Zagon Methods and compositions for treatment of epithelial wounds
HK1206978A1 (en) 2012-04-17 2016-01-22 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
US20140170593A1 (en) * 2012-12-18 2014-06-19 Oltuse, Llc Patch for non-invasive pain relief
CA2919892C (en) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
JP2016529328A (ja) 2013-09-10 2016-09-23 インシス・ファーマ・インコーポレーテッド 舌下ブプレノルフィンスプレー
US9839611B2 (en) 2013-09-10 2017-12-12 Insys Development Company, Inc. Sublingual buprenorphine spray
US9867818B2 (en) 2013-09-10 2018-01-16 Insys Development Company, Inc. Sublingual buprenorphine spray
US9918981B2 (en) 2013-09-10 2018-03-20 Insys Development Company, Inc. Liquid buprenorphine formulations
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
CA2954370A1 (en) 2014-07-08 2016-01-14 Insys Pharma, Inc. Sublingual naloxone spray
US10722510B2 (en) 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10617686B2 (en) 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
TW201613590A (en) * 2014-09-12 2016-04-16 Purdue Pharma Lp Systems and methods for attenuating opioid-induced euphoria
KR102102513B1 (ko) * 2014-10-14 2020-04-20 히사미쓰 세이야꾸 가부시키가이샤 첩부제
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US10496793B1 (en) 2014-12-15 2019-12-03 Mckesson Corporation Systems and methods for determining eligibility in a prescription safety network program
US10010543B1 (en) 2014-12-23 2018-07-03 Barr Laboratories, Inc. Transdermal dosage form
CA2974324A1 (en) 2015-01-28 2016-08-04 Zita S. Netzel Drug delivery methods and systems
WO2016145373A1 (en) 2015-03-12 2016-09-15 Chrono Therapeutics Inc. Craving input and support system
WO2017040607A1 (en) * 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
GB201520390D0 (en) * 2015-11-19 2016-01-06 Euro Celtique Sa Composition
US20170273974A1 (en) * 2016-03-24 2017-09-28 Medrx Co., Ltd Patch preparations with misuse prevention features
WO2018075665A1 (en) * 2016-10-20 2018-04-26 Axim Biotechnologies, Inc. Chewing gum composition comprising cannabinoids and opioid agonists and/or antagonists
CN110121344A (zh) * 2016-12-28 2019-08-13 久光制药株式会社 含布托啡诺的贴附剂
EP3565617A1 (en) 2017-01-06 2019-11-13 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
JP6773897B2 (ja) 2017-04-25 2020-10-21 久光製薬株式会社 貼付剤
CN110545816B (zh) 2017-04-25 2023-04-11 久光制药株式会社 贴附剂
CA3068036A1 (en) 2017-06-30 2019-01-03 Purdue Pharma L.P. Use to buprenorphine in combination with an opioid to treat pain
AU2018359336B2 (en) 2017-11-03 2024-06-20 Nirsum Laboratories, Inc. Opioid receptor antagonist prodrugs
JP2021506790A (ja) * 2017-12-14 2021-02-22 エルテーエス ローマン テラピー−ジステーメ アーゲー 塩形態の有効成分を含むマイクロニードルアレイ
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
WO2020012248A1 (en) 2018-07-13 2020-01-16 Alkermes Pharma Ireland Limited Novel naphthylenyl compounds for long-acting injectable compositions and related methods
US10807995B2 (en) 2018-07-13 2020-10-20 Alkermes Pharma Ireland Limited Thienothiophene compounds for long-acting injectable compositions and related methods
US10975099B2 (en) 2018-11-05 2021-04-13 Alkermes Pharma Ireland Limited Thiophene compounds for long-acting injectable compositions and related methods
CA3119992A1 (en) 2018-11-16 2020-05-22 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
CN113226288B (zh) * 2018-12-27 2023-04-28 昱展新药生技股份有限公司 纳曲酮注射型缓释制剂
JP7397095B2 (ja) 2019-05-07 2023-12-12 ニーサム・ラボラトリーズ・インコーポレイテッド オピオイド受容体アンタゴニストプロドラッグ
WO2023022050A1 (ja) * 2021-08-17 2023-02-23 株式会社カネカ アミノアルキルテトラヒドロピラン誘導体

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966940A (en) * 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
FR2519985A1 (fr) * 1982-01-15 1983-07-22 Ugine Kuhlmann Procede perfectionne de fabrication de l'e-caprolactone
US4780320A (en) * 1986-04-29 1988-10-25 Pharmetrix Corp. Controlled release drug delivery system for the periodontal pocket
US4673679A (en) * 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
US5006342A (en) * 1986-12-22 1991-04-09 Cygnus Corporation Resilient transdermal drug delivery device
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5288502A (en) * 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
US5919473A (en) * 1997-05-12 1999-07-06 Elkhoury; George F. Methods and devices for delivering opioid analgesics to wounds via a subdermal implant
US7011843B2 (en) * 1997-10-01 2006-03-14 Lts Lohmann-Therapie Systeme Ag Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system
US6287693B1 (en) * 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
PT2062573E (pt) * 2001-05-01 2012-01-11 Euro Celtique Sa Sistemas transdérmicos que contêm opióides que resistem a violação
US6913760B2 (en) * 2001-08-06 2005-07-05 New England Medical Hospitals, Inc. Drug delivery composition
US7332182B2 (en) * 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
TW200404581A (en) * 2002-04-23 2004-04-01 Alza Corp Transdermal analgesic systems with reduced abuse potential
SI1513532T1 (sl) * 2002-06-10 2007-08-31 Euro Celtique Sa Sistemi za odstranjevanje priprav za transdermalno oddajanje za preprečevanje zlorabe učinkovin, ki jih vsebujejo
ES2290512T3 (es) * 2002-08-09 2008-02-16 Grunenthal Gmbh Antagonistas del receptor opioide en sistemas transdermicos que contienen buprenorfina.
ATE444296T1 (de) * 2002-10-25 2009-10-15 Euro Celtique Sa Analoga und prodrugs von buprenorphin
US7524515B2 (en) * 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
DE602004024963D1 (de) * 2003-03-13 2010-02-25 Controlled Chemicals Inc Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer
US20040191301A1 (en) * 2003-03-27 2004-09-30 Van Duren Albert Philip Transdermal device having a phase change material
US20080020028A1 (en) * 2003-08-20 2008-01-24 Euro-Celtique S.A. Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
WO2005025549A2 (en) * 2003-09-10 2005-03-24 Noven Pharmaceuticals, Inc. Multi-layer transdermal drug delivery device
EP2269606A3 (en) * 2003-10-30 2012-04-25 ALZA Corporation Transdermal analgesic systems having reduced abuse potential
ES2324719T3 (es) * 2004-02-23 2009-08-13 Euro-Celtique S.A. Dispositivo de administracion transdermica de opioides con resistencia al abuso.
EP1928881A2 (en) * 2005-08-19 2008-06-11 Pharmacofore, Inc. Prodrugs of active agents
JP5180092B2 (ja) * 2005-11-22 2013-04-10 オレキシジェン・セラピューティクス・インコーポレーテッド インスリン感受性を増すための組成物および方法
EP1968539A2 (en) * 2005-12-13 2008-09-17 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
WO2008036980A1 (en) * 2006-09-22 2008-03-27 Alltranz Inc. Transdermally deliverable buprenorphine prodrugs and abuse-resistant compositions thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4458376A4 (en) * 2022-01-30 2025-05-07 Zhejiang University PH-REACTIVE ANALGESIC FOR TARGETING DAMAGED DORSAL ROOT GANGLION SEGMENT AND USE THEREOF

Also Published As

Publication number Publication date
WO2009120889A2 (en) 2009-10-01
US20090246265A1 (en) 2009-10-01
MX2010010512A (es) 2010-11-09
WO2009120889A3 (en) 2011-01-20
JP2011515495A (ja) 2011-05-19
EP2254561A2 (en) 2010-12-01

Similar Documents

Publication Publication Date Title
US20090246265A1 (en) Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists
CA2795158C (en) Abuse-deterrent transdermal formulations of opiate agonists and agonist-antagonists
CA2795156C (en) Transdermally deliverable opioid prodrugs, abuse-resistant compositions and methods of using opioid prodrugs
CA2955247C (en) Abuse deterrent opiod/opiod-antagonist transdermal patch
US8309568B2 (en) Transdermally deliverable opioid prodrugs, abuse-resistant compositions and methods of using opioid prodrugs
CA2679316C (en) Morphine composition for transdermal absorption, morphine composition storing unit and transdermal absorption preparation using the same
US20190328681A1 (en) Transdermal patch
JPH04128231A (ja) ブプレノルフインを経皮的にデリバーすることからなるコ力インおよびヘロイン耽溺の治療方法
US10874658B2 (en) Sublingual opioid formulations containing naloxone

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20150326

FZDE Discontinued

Effective date: 20150326